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Chronic periodontitis is an inflammatory disease caused by the formation of oral
microbial biofilms. Periodontitis is associated with general health and not only oral
diseases. Porphyromonas gingivalis is a well-known keystone pathogen for periodontitis
and is associated with several systemic diseases, such as diabetes mellitus and
Alzheimer’s disease. We previously developed a system for screening periodontitis using
P. gingivalis-specific serum immunoglobulin G (IgG) in an enzyme-linked immunosorbent
assay with a sensitivity of 0.774 and a specificity of 0.586 and an area under the receiver
operating characteristic curve of 0.708. However, the antigens elicited non-specific
responses, since they were obtained from whole extracts of sonicated cultured bacteria.
The purpose of this study was to identify antigens ideal for a sensitive and specific
serum test. We identified the specific antigens using immunoaffinity columns immobilized
with IgG antibodies from periodontitis patients. Liquid chromatography-tandem mass
spectrometry identified 29 antigens from the elutes. Recombinant proteins for these
candidates were synthesized using the wheat germ cell-free translation system and
screened by dot blot analysis with serum from the columns. Three of the 16 candidates
that reacted showed strongest affinities upon dot blot analysis; they included outer
membrane protein 28, cysteine proteases, lysine gingipain Kgp, and arginine gingipain
RgpA. Outer membrane protein 28 was not suitable for screening P. gingivalis infection
because of its high false-negative rates. Kgp and RgpA were unstable antigens since
they underwent self-digestion. They were made stable by substituting the active cysteine
residues in Kgp and RgpA with alanine using site-directed mutagenesis. Using the
modified antigens, we demonstrated that the patient serum IgG level against RgpA was
the highest among all the antigens expressed in P. gingivalis. Moreover, the N-terminus of
recombinant RgpA was excellent in differentiating between diseased and non-diseased
states (with sensitivity of 0.85, specificity of 0.9, and area under the curve of 0.915).
Although dot blot analysis was the only experiment used, the N-terminus of RgpA is
an excellent antigen to immunologically test for P. gingivalis infection, especially for
estimating the risks for periodontitis-associated systemic diseases. In conclusion, we
have developed a P. gingivalis antigen for screening periodontitis.
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INTRODUCTION
Periodontitis is an inflammatory immune response elicited by the
polymicrobial infection of anaerobic Gram-negative bacteria in
subgingival plaques (1). This inflammatory condition damages
periodontal tissues and characteristically results in the loss
of alveolar bone surrounding the teeth. Periodontitis includes
localized as well as chronic weak systemic inflammation in the
oral cavity (2). Recent studies have shown that periodontitis
is associated with systemic inflammatory diseases. Severe
periodontal inflammation deteriorates the glycemic control in
patients with diabetes mellitus; moreover, periodontitis is a risk
factor for atherosclerotic cardiovascular disease, non-alcoholic
fatty liver disease, and Alzheimer’s disease (3–8). Therefore,
the level of periodontal inflammation and immune responses
could be used to diagnose the risk factors for developing
systemic diseases.
Periodontitis can be diagnosed upon general examination,
such as the prevalence of periodontal pockets and extent
of alveolar bone loss, that primarily show the degree of
periodontal tissue damage. Humoral immunological responses
against periodontal pathogens can be determined by measuring
the serum immunoglobulin G (IgG) antibody level against
periodontal pathogens using enzyme-linked immunosorbent
assays (ELISA) (9). It is recognized that infection with
periodontal bacteria leads to humoral immunological responses
and elevates the serum IgG antibody levels against pathogens
(9). Porphyromonas gingivalis, a black-pigmented Gram-negative
anaerobic bacterium, has been considered to be the keystone
pathogen in periodontitis (10). Thus, the progression of
periodontitis is associated with high serum IgG antibody levels
against P. gingivalis (8, 11–13). It has also been reported that
the serum IgG antibody level against P. gingivalis reduces with
decreasing bacterial counts in the periodontal pockets upon
treatment (11–13). In our previous study, we have demonstrated
the utility of serum IgG antibody level against P. gingivalis in
screening chronic periodontitis patients (9, 14). A recent study
showed that serum IgG antibodies against periodontal pathogens
serve as potential biomarkers that can be used to determine the
risk factors for systemic diseases (15, 16). Univariable logistic
regression analyses have shown serum IgG levels against P.
gingivalis to be associated with cardiovascular disease (15).
However, testing the serum IgG level for periodontal
pathogens is not performed during a clinical examination. One
of the reasons for this is that using antigens from sonicated
preparations of cultured pathogens in the media results in non-
specific immunoreactions by IgG antibodies. Another reason
could be the difficulty in standardizing the bacterial antigens
in ELISA. It is difficult to precisely control the components of
sonicated preparations from one study to another. A variety
of P. gingivalis antigens with high immunogenicity have been
reported; thus, it is possible to utilize and standardize a single
or a combination of purified recombinant antigens, thereby
enabling the development of a more specific IgG level test for
periodontitis. Comparisons of antigens eliciting high serum IgG
levels against P. gingivalis as a whole need to be performed;
antigen(s) that have the capacity to discriminate between
periodontitis patients and healthy individuals and that can be
used for diagnosis remain to be discovered.
The aim of this study is to identify the P. gingivalis antigen(s)
that are specifically recognized by serum IgG with high levels
in periodontitis patients as compared to those in healthy
individuals. We employed liquid chromatography-tandem mass
spectrometry (LC-MS/MS) for screening the antigens recognized
by patient serum IgG antibodies. Mass spectrometry is a unique
and powerful analytical tool in that it can directly analyze any
biological molecule susceptible to ionization. Recently, these
proteomic analyzes by MS have been essential tools especially in
periodontics (17, 18).We identified 29 different components in P.
gingivalis and demonstrated that RgpA was the most appropriate
antigen for screening periodontitis patients.
MATERIALS AND METHODS
Study Design
Supplementary Figure 1 shows a schematic procedure for
this study. This study comprised three screening steps to
identify the antigens specifically recognized by serum IgG
antibodies in periodontitis patients compared to those in
healthy subjects, thereby establishing a novel antigen for
the diagnosis of periodontitis. The first step included the
purification of the sonicated crude protein extract from P.
gingivalis strains FDC381 and SU63 using immunoaffinity
columns immobilized with patient serum IgG antibodies with
a high level against P. gingivalis FDC381 and SU63. The elutes
were collected from the affinity columns and antigens were
identified by liquid chromatography–tandem mass spectrometry
(LC-MS/MS). Recombinant proteins were synthesized using
the wheat germ cell-free translation system based on the 29
antigens that were identified by LC-MS/MS. In the second
step, the immunogenicity of the 29 recombinant antigens
were determined by dot blot analysis with sera used in the
immunoaffinity columns. The candidate antigens that reacted
with the serum IgG antibodies were selected and used in the
third screening step. In this step, we determined the serum
IgG level against the candidate antigens in 20 periodontitis
patients and 10 healthy subjects using dot blot analysis. Finally,
receiver operative characteristic (ROC) curves were analyzed to
determine their capability to discriminate between the antigens
showing significantly higher IgG levels in periodontitis patients
than those in healthy subjects as per a published protocol (14).
Serum Samples
Serum was collected from a total of 26 patients with periodontitis
(11 males and 15 females with a mean ± standard deviation
age of 52 ± 12 years). The control group comprised 10 healthy
subjects without alveolar bone loss (five males and five females
with a mean ± standard deviation age of 34 ± 5 years). The
characteristics of all the individuals are shown in Table 1. We
obtained six sera samples from patients (b1–b3 and c1–c3) with
high IgG levels against P. gingivalis FDC381 and SU63. These
were used in the immunoaffinity columns as part of the first and
second steps for screening as described above. Levels of the serum
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TABLE 1 | Profile of the healthy control group and periodontitis patients.
Number
in figure
IgG level
(FDC381)
IgG level
(SU63)
Number
of present
teeth
Bone loss
(Schei
value)
Healthy H1 −0.383 0.155 28 N.D.
H2 −0.322 −0.239 28 N.D.
H3 −0.557 −1.367 28 N.D.
H4 −0.152 0.425 28 N.D.
H5 −0.536 −1.307 28 N.D.
H6 −0.562 −1.201 28 N.D.
H7 (a1) −0.634 −1.446 28 N.D.
H8 (a2) −0.647 −1.365 28 N.D.
H9 −0.635 −1.321 28 N.D.
H10 (a3) −0.666 −1.445 28 N.D.
Periodontitis b1 5.450 10.180 N.A. N.A.
b2 7.550 5.070 N.A. N.A.
b3 13.320 5.850 N.A. N.A.
c1 1.800 0.060 N.A. N.A.
c2 15.110 9.080 N.A. N.A.
c3 13.360 5.520 N.A. N.A.
P1 1.093 0.054 17 77.06
P2 2.365 1.558 17 55.59
P3 0.000 −0.813 10 55.50
P4 1.211 −0.504 27 53.33
P5 1.912 0.269 28 51.79
P6 1.052 −0.202 24 47.50
P7 2.415 0.755 22 44.77
P8 37.587 11.373 18 43.06
P9 0.040 −0.179 18 42.22
P10 3.901 3.246 25 38.80
P11 0.647 1.137 29 11.03
P12 1.207 0.648 30 15.83
P13 2.474 0.603 29 16.90
P14 0.000 −0.521 27 17.04
P15 8.073 1.324 25 19.80
P16 2.270 0.814 16 20.00
P17 −0.147 0.510 28 20.54
P18 18.572 4.248 30 20.67
P19 0.095 −0.378 28 20.89
P20 1.657 −0.454 17 23.53
Serum samples were obtained from 10 healthy subjects without bone loss (five male
and five females; mean ± standard deviation age, 34 ± 5 years) and 26 patients with
periodontitis (11 males and 15 females; mean ± standard deviation age, 52 ± 12 years).
Serum IgG levels against P. gingivalis FDC381 and SU63 were measured by enzyme linked
immunosorbent assay. The extent of bone loss was measured by the methods of Schei.
Schei indices were classified as: <25% represents mild bone loss and >35% represents
severe bone loss.
IgG levels of healthy subjects were usually lower than 1. In addition, healthy subjects had
28 teeth and no bone loss was detected (shown as N.D.). Meanwhile, numbers of teeth
and bone loss of periodontitis patients used for affinity column (b1-b3 and c1-c3) were
not available (shown as N.A.).
IgG against P. gingivalis FDC381 and SU63 were quantified by
ELISA as described in previously (9).
Samples from 10 patients with mild alveolar bone loss (P11–
P20 bone loss; 18.6 ± 7.2%) and 10 patients with severe
alveolar bone loss (P1–P10 bone loss; 51.0 ± 21.5%) were
used for performing dot blot analysis as part of the third
screening step. Alveolar bone loss in periodontitis patients
was measured by the methods described by Schei (19) and
expressed by the Schei index. Severity of bone resorption
was classified according to the Schei indices: <25% represents
mild bone loss; 25–35% represents moderate bone loss; and
>35% represents severe bone loss. All patients signed an
informed consent form for participation in the study and
for the use of their biological samples. This study was
approved by the Ethical Committee of Okayama University
Graduate School of Medicine, Dentistry, and Pharmaceutical
Sciences (approval no. 624).
Immunoaffinity Chromatography
To select the antigens recognized by serum IgG in periodontitis
patients, we used immunoaffinity columns based on the
interaction between specific immobilized IgG antibodies and
their target antigens (20). As previously reported (21), IgG
antibodies in the serum from periodontitis patients exhibited
two recognition patterns against the total proteins extracted from
P. gingivalis that were observed as clear bands (b1–b3) and
smears (c1–c3) on the Western blots (Supplementary Figure 2).
Each serum type recognized different sizes of the antigens.
Therefore, we used the two types of sera in the immunoaffinity
columns. The sera obtained from three individuals in each
group (healthy, clear bands, and smears) were mixed with the
binding buffer (50mM tartaric acid buffer with 3M sodium
chloride; pH 9.0). After washing protein G Sepharose beads
(GE Healthcare Bio-Sciences, Rydalmaere, NSW, Australia)
with the binding buffer, the sera mixed with the binding
buffer were reacted with protein G Sepharose beads in Econo-
pac columns (Bio-Rad Laboratories, Hercules, CA) on a
rocking platform. After that binding process, the columns
were washed with binding buffer and then crosslinking
was performed to covalently attach antibodies to Protein
G supports using the crosslinker BS3 (Pierce). Before the
crosslinking, a 50mM solution of BS3 was prepared, by
dissolving 10mg of BS3 in 6.8mL of crosslinker buffer
(0.2M triethanolamine hydrochloride, pH 8.0). Blocking was
performed with 0.2M ethanolamine hydrochloride (pH 8.0).
Each column was washed with elution buffer (0.1M glycine
hydrochloride, pH 2.8) and stored for further use in 50mM
Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl,
pH 7.5).
Whole protein extracts of P. gingivalis FDC381 and SU63
were purchased from the Institute of Immunology Co., LTD
(Tokyo, Japan) and were dissolved in phosphate-buffered saline
containing 0.03% sodium dodecyl sulfate (SDS), 0.005% Brij-
35, and 0.2% CHAPS. P. gingivalis FDC381 and SU63 extracts
(133 µg/1.5mL) were injected into the immunoaffinity columns
to purify the antigens recognized by serum IgG antibodies.
The columns were washed three times with 20mM Tris-HCl
containing 0.005% Brij-35, 500mM sodium chloride, and 0.1%
CHAPS (pH 7.5). The antigens were eluted from each column
using 0.05% trifluoroacetic acid, lyophilized, and stored for
future use.
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Sodium Dodecyl Sulfate-Polyacrylamide
Gel Electrophoresis (SDS-PAGE) and
Western Blot Analysis
SDS-PAGE and Western blotting were performed as described
previously (22). After SDS-PAGE, gels were either subjected to
the Western blotting protocol or stained with 10% (v/v) acetic
acid, 45% (v/v) methanol, and 0.1% (w/v) Coomassie brilliant
blue R-250 for 1 h and subsequently de-stained with 10% (v/v)
acetic acid and 30% (v/v) methanol overnight. For western blot
analysis, SDS-PAGE gels were blotted on polyvinylidene fluoride
membranes (EMDMillipore, Billerica, MA, USA) using the iBlot
Dry Blotting System (Thermo Fisher Scientific, Inc., Waltham,
MA, USA) as described previously (22). Serum samples from
periodontitis patients were used at a final dilution of 1:2,500 in
tris-buffered saline (TBS; 10mM Tris-HCl buffer, pH 7.5, 0.9%
sodium chloride) containing 3% (w/v) skimmed milk (M-TBS)
with 0.1% Tween 20. Horseradish peroxidase-conjugated goat
anti-human IgG secondary antibody (Chemicon International,
Inc., Temecula, CA, USA) was used for detection at a dilution
of 1:5,000 in M-TBS.
Liquid Chromatography-Tandem Mass
Spectrometry (LC-MS/MS)
Antigens eluted from the immunoaffinity columns were
separated by SDS-PAGE. Protein bands were excised using a
scalpel and samples were subjected to trypsin in-gel digestion
using the robotic InvestigatorTM ProGest workstation (Digilab,
Inc., Hopkinton, MA, USA) that automatically performed the
washing, alkylation, enzyme activation, and thermal incubation
cycles. Analysis of the digested extracts in 0.1% formic acid
were performed after LC-MS/MS using the C12 Jupiter high
performance liquid chromatography column and LTQ Orbitrap
XL mass spectrometer (Thermo Fisher Scientific, Inc.). The flow
rate was maintained at 300 nL/min. Mass spectra were recorded
in the data-dependent mode from the six most abundant ions.
Raw data from the mass spectrometer were used as input for
the Mascot database (www.matrixscience.com) with a peptide
tolerance of ±10 ppm and an MS/MS tolerance of ±0.5; fixed
modifications—carbamidomethyl; variable modifications—
oxidation, acetylation, pyroglutamination, and deamidation;
and up to two missed cleavages by trypsin (23). Protein and
peptide matches were filtered and validated using the Scaffold
algorithm (www.proteomesoftware.com) (23). Protein identity
was accepted at a >95% probability and contained at least two
identified peptides (at ≥95%).
Construction of Recombinant Antigens
Recombinant proteins of the 29 antigens identified by LC-
MS/MS were prepared using the wheat germ cell-free translation
system (CellFree Sciences, Ehime, Japan) as described previously
(24). The complete target genes including a sequence of signal
peptide were amplified by polymerase chain reaction. The
primers were designed (Supplementary Table 1) to contain
restriction sites and attB1/B2 sequences for the subsequent
cloning protocol. The attB1 sequence (5′-GGGGACAAGTTT
GTACAAAAAAGCAGGCT-3′) was added to the 5′ ends of each
of the forward primers and the attB2 sequence (5′-GGGGACC
ACTTTGTACAAGAAAGCTGGGT-3′) was added to the 5′ ends
of each of the reverse primers. The reaction was performed
in a volume of 50 µL using Ex-Taq polymerase (Takara Bio,
Inc., Shiga, Japan) under the conditions recommended by the
manufacturer with 20 pmol of forward and reverse primers
and 100 ng of the cDNA. The reaction conditions included 35
cycles of denaturation at 98◦C for 60 s, annealing at 58◦C for
30 s, and extension at 72◦C for 2.5min with a final extension
at 72◦C for 10min. We employed the Gateway cloning protocol
by Invitrogen (Thermo Fisher Scientific, Inc.) for subcloning
the genes of interest into a set of destination vectors (25).
This molecular biology-based technique efficiently transfers
DNA fragments between plasmids using a proprietary set of
recombination sequences like the attB1/B2 sites. The modified
target gene sequences were ligated into the pDONR221 vector
(Thermo Fisher Scientific, Inc.). Subsequently, these plasmids
were transformed into standard competent E. coli DH5α cells
(Takara Bio, Inc.). Plasmids were isolated from cultured E.
coli DH5α and digested with the respective restriction enzyme
(Supplementary Table 1). The digested gene fragments were
cloned into the corresponding sites of the expression vector
pEU-E01-GST-TEV (CellFree Sciences) in frame with the gene
encoding glutathione S-transferase (GST) at the N-terminus of
the target gene.
Synthesis and purification of the recombinant proteins were
performed using the CellFree Sciences kit. Briefly, transcription
and translation were performed using the CFS-TRI-1240G kit
(CellFree Sciences) and the expression plasmids, as described
above. In vitro transcription was performed at 37◦C for 6 h in a
reaction buffer containing 100 ng/µL of the plasmids, 1 unit/µL
of SP6 RNA polymerase, 1 unit/µL of RNase inhibitor, 2.5mM
NTPs, and 1× transcription buffer that was supplied with the
kit. In vitro translation was performed using 5.5mL of SUB-
AMIX (proprietary buffer containing all the amino acids) with
250 µL of the transcription products, 1 µL of creatine kinase (20
mg/mL), and 250 µL of WEPRO1240G supplied with the kit for
16 h at 17◦C. Glutathione Sepharose 4B gel (GE Healthcare Bio-
Sciences) was used to purify the GST-tagged proteins. Samples
from each purification step were analyzed by SDS-PAGE.
Inactivation of Protease Activity Using
Cysteine Residue Mutants
Two of the recombinant antigens that we identified, Lys-
gingipain (Kgp) and Arg-gingipain (RgpA), are strong cysteine
proteases that are capable of self-digestion and, thus, are unstable.
To prevent this self-digestion, the cysteine residues C477 on Kgp
and C471 on RgpA were substituted with alanine residues by
site-directed mutagenesis using the PrimeSTAR R© mutagenesis
basal kit (Takara Bio, Inc.) according to the kit protocol. The
following primers were designed to introduce the mutations (the
mutated regions have been underlined): C477 (TGT) in Kgp
(5′-ATTACAGCTCAATTCGATTA-3′/5′-AGCGCAGTTGCC
AATAGCTA-3′); C488 (TGC) in Kgp (5′-CCTTCGGAGAGG
TAATAACT-3′/5′-CAGGCTGTACATAATCGAAT-3′); C471
(TGT) in RgpA (5′-GTGAATGGCGATTTCCTATT-3′/5′-AGC
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AGCTACGTCGAAAATAA-3′); C482 (TGT) in RgpA (5′-CTTT
CGCAGAAGCATTGATG-3′/5′-CAGGCATGCTGAATAGG
AAA-3′). The desired mutations were confirmed by DNA
sequencing and the mutants were expressed and purified by the
methods described above.
Dot Blot Analysis
Dot blots were used to analyze the reactivity of recombinant
antigens to patient serum IgG. The recombinant antigens
were diluted with TBS to a final concentration of 12.5µg/mL.
Aliquots of 4 µL of the diluted proteins were spotted on
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA).
After the spots had dried, the membranes were blocked
with M-TBS. The blocked membranes were then incubated
with serum at a dilution of 1:1,000 in M-TBS for 12 h
at room temperature. The membranes were washed with
TBS containing 0.05% Tween 20 and the antibody bound
to the membrane was detected with horseradish peroxidase-
conjugated goat anti-human IgG secondary antibody (Chemicon
International, Inc.). After colorimetric detection using naphthol,
the intensities of the spots on the blots were quantified using
the computerized densitometry ImageQuant LAS4000 Digital
System (GE Healthcare Bio-Sciences) and analyzed using the
ImageQuant TL software (GE Healthcare Bio-Sciences). The
spots on the blots were scanned in the “array analysis” mode.
Blank areas without signals of the recombinant proteins were
used for subtracting background noise and normalization.
Statistical Analysis
Statistical analysis was performed using Ekuseru-Toukei 2015
(Social Survey Research Information Co., Ltd., Tokyo Japan). The
Mann-Whitney U test was used to compare the differences in
serum IgG levels between the periodontitis patients and healthy
individuals. The cut-off values for IgG levels were obtained
from the ROC curves. Diagnostic efficacy was calculated and
represented as sensitivity and specificity. The area under the ROC
curve was used to evaluate the capacity to discriminate between
the periodontitis patients and healthy individuals. The values for
area under the ROC curve (AUC) were categorized as: 0.5–0.7
represents no to low discrimination; 0.7–0.8 represents moderate
discrimination; 0.8–0.9 represents excellent discrimination; and
>0.9 represents outstanding discrimination.
RESULTS
Identification of P. gingivalis Antigens
Recognized by Periodontitis Patient Sera
IgG antibodies in the serum of periodontitis patients exhibited
two recognition patterns against the whole extracts of P.
gingivalis including a group of clear bands or smears on
Western blots (21). The clear bands (Supplementary Figure 2B)
mainly corresponded to ∼30–3 kDa antigens, while the smears
(Supplementary Figure 2C) included a wide range of antigens
(25–250 kDa). Moreover, it has been reported that the smears
on the Western blots partly comprised the P. gingivalis
lipopolysaccharide (21, 26). Therefore, we used these sera
from two groups of periodontitis patients (b1-b3 and c1-c3
in Supplementary Figure 2) and that from healthy individuals
(a1-a3 in Supplementary Figure 2) to purify the antigens using
immunoaffinity columns. Whole protein extracts containing the
P. gingivalis FDC381 and SU63 antigens that were recognized by
the serum IgG antibodies were separated in the eluted fractions
from the immunoaffinity columns (Figures 1A,C). As shown in
Figures 1B,D, immunoreactivity of the separated proteins in the
elutes was confirmed using mixed sera from the immunoaffinity
columns (the clear bands, smears, and healthy individuals) by
Western blot analysis. The purified antigens in the elutes of
FDC381 and SU63 were analyzed by LC-MS/MS using the
Thermo Fisher LTQ Orbitrap XL. As shown in Table 2, 29
antigens were identified by the Mascot database and Scaffold
algorithm using LC-MS/MS data that were enriched in the
patient sample columns as compared to the columns for the
healthy group. Although we prepared immunoaffinity columns
containing each group of serum IgG antibody on protein G
Sepharose (clear bands and smears), the profile of the antigens
eluted from each immunoaffinity column was mostly similar
(data not shown). These antigens comprised six outer membrane
proteins, six heme-binding proteins, nine enzymes, two fimbrillin
proteins, and six unknown proteins. Many of the antigens have
been reported to be strongly immunogenic, such as heme-
binding proteins, outer membrane proteins, fimbrillins, and the
gingipain family of enzymes. The antigens No.7, 11, 19, 26, and
29 were identified not only from patients’ columns but also from
healthy subjects’ columns. However, spectral count obtained by
LC-MS/MS defined as the total number of spectra identified for
a protein from healthy columns was quite smaller than that from
patient columns (Data not shown). Since the overlapped antigens
had the possibility of showing higher antibody level in patient
sera compared to healthy sera, we synthesized all the 29 antigens,
identified and listed in Table 2.
Selection of Recombinant P. gingivalis
Antigens Recognized by Periodontitis
Patient Sera
The 29 antigens identified and listed in Table 2 were translated
in vitro using the wheat germ cell-free translation system.
The purity of every recombinant protein was determined by
SDS-PAGE (Figure 2A). Recombinant antigens No. 25, 27, and
28 were smaller than their predicted sizes or were observed
as multiple bands. Due to their strong protease activity,
recombinant antigen numbers 25 and 27 that were Lys-gingipain
(Kgp) and Arg-gingipain (RgpA), respectively, underwent
self-digestion and subsequently were unstable. As shown in
Figure 2B, dot blot analyses confirmed the immunogenicity of
each recombinant antigen against the mixed serum (comprising
clear bands, smears, and healthy control samples) used in the
immunoaffinity columns. Recombinant forms of the major outer
membrane proteins RagA (antigen 26), RagB (antigen 29), and
fimbriae proteins FimA (antigen 13) (27–29), that have been
reported to be antigens inducing high levels of serum IgG,
showed low or no signal on the blot (Figure 2B). The intensities
of the spots for antigens No. 1–4, 7–9, 11, 15, 17, 18, 20, 21, 23,
25, and 27 were relatively strong using the periodontitis patient
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FIGURE 1 | Protein contents in various fractions after purification using immunoaffinity columns. SDS-PAGE was used to separate the proteins from each fraction for
strains FDC381 (A) and SU63 (C). 10 µL of each fraction were loaded into each gel lane. Immunoreactivities of the separated proteins in the elutes for strains FDC381
(B) and SU63 (D) were confirmed by Western blot analysis with mixed serum used in the immunoaffinity columns as described in Supplementary Figure 2.
Approximately, 2 µg of each protein was blotted on the membrane, and pooled sera used for affinity column (three subjects in each) were used at a dilution of
1:2,500. H: healthy control, B: the serum type of clear bands, S: the serum type of smear bands.
mixed serum as compared to those using serum from healthy
individuals. These antigens included heme-binding proteins, the
gingipain family of enzymes, and outer membrane proteins that
have been reported to be antigens capable of inducing high levels
of serum IgG or strong virulence factors. The remaining 13
recombinant antigens showed low or no signal on the blot.
Inactivation of the Protease Activity of
Antigens 25 and 27 (Gingipains) by
Modifying Their Cysteine Residues
Gingipains, a group of lysine (Kgp) or arginine (RgpA)
specific cysteine proteases, are a major group of virulence
factors in P. gingivalis. Due to their strong protease activity,
we inactivated the protease activities of recombinant antigen
numbers 25 (Kgp) and 27 (RgpA) and stabilized them. The
protease activity of RgpA and Kgp are regulated by cysteine
residues C471 on RgpA and C477 on Kgp, respectively (30–
32). Subsequently, cysteine residues C477 in the recombinant
Kgp and C471 in the recombinant RgpA were substituted
with alanine residues to inhibit their protease activities. All
the modified antigens maintained their immunogenicity against
the serum obtained from the periodontitis patients (Figure 3B).
Therefore, we used the 25A and 27A antigens wherein C477
and C471 were substituted with alanine residues, respectively, for
further experiments.
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TABLE 2 | List of P. gingivalis antigens recognized by patients’ serum IgG.
No. Identified proteins Accession# MW Characteristics
1 Hypothetical protein with
Zinc carboxypeptidase
domain
gi|188994199 (+1) 92 kDa Unknown
2 Hypothetical protein
PG1881
gi|34541489 53 kDa Unknown
3 Hypothetical protein
PGN_0291
gi|188994155 134 kDa Unknown
4 Hypothetical protein
PGN_1611
gi|188995475 (+1) 53 kDa Unknown
5 Hypothetical protein
PGN_0477
gi|188994341 (+1) 61 kDa Unknown
6 Hypothetical protein
PGN_0860
gi|188994724 (+1) 39 kDa Unknown
7 53 kDa major outer
membrane protein
gi|5832527 54 kDa Outer membrane
protein
8 35 kDa hemin binding
protein
gi|188994523 (+1) 38 kDa Iron binding
protein
9 Iron hemin transport
FetB
gi|188994569 (+2) 33 kDa Iron binding
protein
10 NAD-dependent
glutamate
dehydrogenase
gi|150842 (+1) 49 kDa Enzyme
11 Phosphoserine
aminotransferase
gi|34540980 40 kDa Enzyme
12 TonB-linked receptor
(Tlr)
gi|188994547 (+1) 79 kDa Receptor
13 Fimbrilin gi|34541709 (+1) 41 kDa Fimbriae
14 Minor component FimE gi|188994049 61 kDa Fimbriae
15 HmuY gi|119392294 (+1) 24 kDa Iron binding
protein
16 M24 family peptidase gi|34540922 67 kDa Proteinase
17 Glyceraldehyde
3-phosphate
dehydrogenase, type I
gi|34541701 36 kDa Enzyme
18 Ferritin gi|34540987 19 kDa Iron binding
protein
19 Serine
hydroxymethyltransferase
gi|34539916 47 kDa Enzyme
20 Outer membrane
lipoprotein Omp28
gi|34541744 32 kDa Enzyme
21 Probable lysyl
endopeptidase
precursor
gi|188995280 (+1) 103 kDa Proteinase
22 Quinone family NAD(P)H
dehydrogenase
gi|34541436 20 kDa Enzyme
23 DNA-binding protein
from starved cells Dps
gi|188995900 (+2) 18 kDa DNA binding
protein
24 Immunoreactive 42 kDa
antigen PG33
gi|34540489 42 kDa Outer membrane
protein
25 Lysine-specific cysteine
proteinase
(Lys-gingipain, Kgp)
gi|1314751 187 kDa Proteinase
26 RagA protein gi|34540042 (+1) 112 kDa TonB-linked
receptor antigen
27 Arginine-specific
cysteine proteinase
(Arg-gingipain, RgpA)
gi|188995833 (+2) 185 kDa Proteinase
28 Outer membrane protein
41 precursor
gi|188994593 (+2) 43 kDa Outer membrane
29 RagB lipoprotein gi|34540043 56 kDa Lipoprotein
The antigens collected by immunoaffinity columns were analyzed using the Thermo Fisher
LTQ Orbitrap XL (LC-MS/MS). The LC-MS/MS data were analyzed using the Mascot
database (www.matrixscience.com) and Scaffold algorithm (www.proteomesoftware.
com) for protein identification.
Serum IgG Level Against Candidate
Antigens Obtained by Dot Blot Analysis
In this study, serum IgG levels were quantified using the
intensities of the spots from the dot blots. Dot blot analysis
included 20 patients with periodontitis and 10 healthy
individuals. Periodontitis patients comprised 10 patients
each with mild alveolar bone loss (P11-P20) or severe alveolar
bone loss (P1-P10) as measured by the methods of Schei (19).
Antigens No. 1–4, 7-9, 11, 15, 17, 18, 20, 21, 23, 25A, and
27A were selected from our previous results (Figures 2, 3) and
spotted on the membrane (Figure 4A), that was then incubated
with the serum (Figures 4B,C). As shown in Figure 4D, the
intensities of the spots on each membrane were quantified
using ImageQuant TL as described in Materials and Methods.
Although the average IgG level against antigens No. 1, 4, 8,
and 21 was relatively high, the interaction was not specific
to the serum from periodontitis patients. The levels for the
periodontitis patient’s serum IgG against antigens number 20 (p
= 0.009), 25A (p= 0.013), and 27A (p=0.005) were significantly
higher than those using the serum from healthy individuals.
Serum IgG levels did not correlate with the severity of alveolar
bone loss (data not shown).
ROC Curve Analysis for the Potential Use
of Recombinant Antigens in the Diagnosis
of Periodontitis
The ability of the recombinant antigens to distinguish
periodontitis patients from healthy individuals was analyzed
using ROC curves and the values for AUC. ROC curves for
antigen numbers 20, 25A, and 27A were obtained by plotting
the sensitivity and specificity values calculated using the spot
intensities shown in Figure 4. The values for AUC with a 95%
confidence interval and sensitivity/specificity with optimal
cut-off have been presented in the lower panel of Figure 5.
The values for the remaining recombinant antigens (1–4, 7–9,
11, 15, 17, 18, 20, 21, 23, 25A, and 27A) have been listed in
Supplementary Figure 3. The values for AUC were categorized
as: 0.5–0.7 that represents low to nil discrimination; 0.7–0.8
that represents moderate discrimination; 0.8–0.9 that represents
excellent discrimination; and >0.9 that represents outstanding
discrimination between periodontitis patients and healthy
individuals. The values of AUC for antigens number 20 (outer
membrane protein 28, Omp28: 0.75), 25A (Kgp: 0.78), and 27A
(RgpA: 0.815) were higher than 0.7, suggesting a capacity to
moderately differentiate periodontitis patients from healthy
individuals. Although the AUC of Omp28 signified moderate
discrimination of the samples (0.7–0.8), half of the patient
sera (10 out of 20) did not completely recognize Omp28
(Figure 4D); thus, indicating a high false negative rate for
this antigen. Therefore, we focused on Kgp and RgpA in our
subsequent experiments.
Using Mutant Antigens to Increase the
Potential for Discrimination by RgpA and
Kgp
In order to provide recombinant proteins stably in high yield
using wheat germ expression system, we synthesized the half
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FIGURE 2 | Immunogenicity of the recombinant P. gingivalis antigens synthesized using the wheat germ cell-free translation system (CellFree Science). (A) SDS-PAGE
analysis of the recombinant proteins to confirm protein purity. The numbers exhibited on top of the SDS-PAGE gels were recombinant protein numbers shown in
Table 2. Approximately, 50 ng of each recombinant protein was loaded into each lane. (B) Serum IgG responses to the recombinant proteins by dot blot analysis with
mixed serum used in the immunoaffinity columns (clear bands, smears, and healthy individuals). Approximately, 50 ng of each protein was blotted on the membrane,
and sera were used at a dilution of 1:2,500. The left panel shows a scheme of the proteins spotted on the membrane. The numbers exhibited on the left panel are the
recombinant protein numbers shown in Table 2.
size of Kgp (25N and 25C) and RgpA (27N and 27C). The N-
terminal fragments of gingipains including the catalytic domains
encompassed amino acid residues from 1 to 856 and 1 to 855
of the Kgp and RgpA nascent polypeptide chains, respectively.
On the other hand, C-terminal fragments started from 862 to
1718 (Kgp) and from 862 to 1703 (RgpA) residues, respectively
and contained hemagglutinin/adhesin region. Using the half size
of recombinant Kgp (25N and 25C) and RgpA (27N and 27C),
dot blot analysis and ROC/AUC analysis were performed the
same way as with the full-length of Kgp and RgpA. As shown
in Figure 6, the half size of recombinants, except for No. 25N,
showed almost the same properties on immunogenicity and
serum IgG antibody levels as the full length of No. 25A and 27A,
respectively. Interestingly, ROC/AUC analysis of antigen No.
27N showed outstanding discriminatory power (AUC = 0.915)
on diagnostic ability to separate periodontitis patients from
the healthy control group (Figure 7), which was significantly
increased compared to antigen No. 27A described in Figure 5.
DISCUSSION
Multiple lines of evidence, including clinical studies, have shown
that the progression of periodontal disease increases the risk
of systemic diseases such as diabetes mellitus and Alzheimer’s
disease (2–7). Thus, there has been increasing amount of effort
from medical specialists to control the occurrence of systemic
diseases based on the periodontal status of individuals. However,
an ideal biochemical marker for detecting the presence of
periodontal disease has not yet been established. The components
in gingival crevicular fluid (GCF) and saliva also have been
investigated as potential biomarkers at predicting disease
progression (33–36). GCF provides site specific information that
represents disease related proteins (33–35). Saliva is considered
as more of an overall assessment of the periodontal disease status
(36). Many of the molecules reported as potential biomarkers
in GCF or saliva were the products of host cells exuded by
the destruction of periodontal tissue and the products derived
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FIGURE 3 | Modification of the cysteine proteases, Lys-gingipain (Kgp; antigen no. 25) and Arg-gingipain (RgpA; antigen no. 27) to inhibit their proteinase activities.
Cysteine residues were substituted with alanine residues on C477 of recombinant Kgp and C471 on recombinant RgpA. (A) SDS-PAGE analysis of the mutant
recombinant proteins. Approximately, 50 ng of each recombinant protein was loaded into each lane. (B) Serum IgG responses to the mutants as determined by the
dot blot analysis. Approximately, 50 ng of each protein was blotted on the membrane, and sera were used at a dilution of 1:2,500.
from the subgingival microbial plaque (33, 36). Therefore, those
molecules may reflect the disease pathophysiology. Meanwhile,
periodontitis is an inflammatory response against periodontal
pathogens, that causes alveolar bone loss. In this aspect, we have
previously reported that serum IgG antibody level against P.
gingivalis by ELISA showed the level of periodontal inflammation
and is an appropriate marker for screening periodontitis patients
(14). Although blood collection is invasive compared to taking
a GCF or a saliva sample, it is minorly invasive and commonly
performed in medical facilities. Furthermore, 50 µL of blood
from fingertip is also good enough for this IgG test (14, 37).
However, testing the serum IgG level for periodontal pathogens
is not commonly performed during a clinical examination except
for research purposes. This is one of the reasons behind the
fact that crude whole protein extracts from P. gingivalis have
been used as antigen sources for testing the IgG level by ELISA.
This causes the test results to vary among institutes. In order
to dissolve this problem, we considered the use of single or a
combination of a small number of purified antigens. Although
several antigens in P. gingivalis have been reported to have high
immunogenicity, it is not clear which P. gingivalis antigens affect
serum IgG levels in periodontitis patients.
In this study we utilized immunoaffinity columns
immobilized with IgG antibodies from periodontitis patients
and identified 29 antigens by Liquid chromatography-tandem
mass spectrometry. In addition, we succeeded in synthesizing
29 recombinant proteins including stabilized gingipain (Kgp
and RgpA) by point mutation. We then examined serum IgG
levels against each of the 16 antigens, which exhibited strong
immunogenicity in Figure 2B, using serum from 10 healthy
individuals and from 20 periodontitis patients (comprising 10
patients each with mild alveolar bone loss or severe alveolar
bone loss). Out of the 16 candidates, the serum IgG levels in
periodontitis patients against Omp28 (antigen number 20),
Kgp (antigen number 25), and RgpA (antigen number 27)
were significantly higher as compared to healthy individuals
(Figure 4); serum IgG levels did not correlate with the severity
of alveolar bone loss (data not shown). Consistent with previous
studies, serum IgG levels did not reflect the extent of tissue
damage (38).
Omp28 is a 28 kDa outer membrane protein found in P.
gingivalis. This protein is a surface adhesion/receptor protein
(39) and is expressed in a variety of P. gingivalis strains.
Based on extensive database searches, no protein exhibited high
homology with Omp28 in other bacterial strains (39). Therefore,
Omp28 has been a potential candidate for the unique diagnostic
for periodontitis. Although serum IgG levels against Omp28
were significantly higher than those in healthy subjects (p =
0.009), half of the serum samples from patients (10 out of
20 periodontitis patients) did not recognize Omp28, indicating
high false negative rates in this study. Moreover, Kgp and
RgpA are well-known cysteine proteases in P. gingivalis and
are the major virulence factors responsible for hindering the
innate host defense mechanisms (40, 41). High serum IgG levels
have been reported against gingipains in periodontitis patients
(42, 43). In this study, we demonstrated that serum IgG levels
against gingipains were the highest compared to a variety of
P. gingivalis antigens that were synthesized using the same
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FIGURE 4 | Analysis of serum IgG responses to recombinant antigens. (A) The panel shows a schematic of the proteins spotted on the membrane used for dot
blotting. The numbers exhibited on the panel were recombinant protein numbers shown in Table 2. The results of individual serum from healthy controls (B: H1–H10)
and patients with periodontitis (C: P1–P20) have been shown. The 20 periodontitis patients that comprised this experiment included 10 patients each with mild
(Continued)
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FIGURE 4 | alveolar bone loss (18.6 ± 7.2) or severe alveolar bone loss (51.0 ± 21.5) as measured by the method of Schei. Approximately 50 ng of each protein was
spotted on the membrane and sera were used at a dilution of 1:2,500. Spot intensities were used for analysis of the dot blots. (D) Spot intensities were normalized
relative to the background signals, and represented as relative intensities. Mean values and standard errors are shown on the right. **P < 0.01; *P < 0.05; H, Healthy
control; P, Patients with periodontitis.
FIGURE 5 | Receiver operative characteristic (ROC) curve analysis to evaluate
the diagnostic capacity of individual recombinant antigens (20, 25A, and 27A)
to distinguish between periodontitis patients and healthy individuals. (A) ROC
curves were generated as described by Ekuseru-Toukei 2010 (Social Survey
Research Information Co., Ltd.) using the spot intensities from the dot blot
analysis (Figure 4). (B) The values of AUC with 95% confidence interval (CI)
and sensitivity/specificity with optimal cut-offs are presented in the lower panel.
translation machinery. ROC curves were drawn to determine
the cut-off based on the serum IgG level values against the
recombinant antigens. The AUC was derived from the ROC
curve that determined the ability of the antigen to discriminate
between periodontitis patients and healthy subjects and diagnose
disease. Kgp (AUC value of 0.78) and RgpA (AUC value of 0.815)
showed moderate discrimination and were the highest compared
to the AUC values of other antigens (Supplementary Figure 3).
Using an optimal cut-off, the specificity of Kgp and RgpA was
satisfactory, whereas the sensitivity was low (Figure 5).
Gingipains are large proteins (180 kDa) encoded by kgp or
rgpA genes that comprise a signal peptide, N-terminal pro-
fragment, Lys- or Arg-specific catalytic domain, and C-terminal
multi-domain hemagglutinin/adhesin (HA1-HA4) region. It has
been observed that serum IgG antibodies in periodontitis
patients are primarily reactive to the hemagglutinin/adhesin
region of Kgp and RgpA (44, 45). The adhesion domain 1
(HA1) and adhesion domain 4 (HA4) of RgpA are significantly
recognized by the serum IgG antibodies in periodontitis patients
as compared to those in healthy subjects (46). The homology
between the hemagglutinin/adhesin regions of the kgp and
rgpA genes is quite high (65–100%), while the homology
between the catalytic domains is low (32%). Moreover, the
shorter templates stably synthesized recombinant proteins in
high yields using the wheat germ expression system. The N-
terminus (antigen 25N and 27N) mainly comprised the catalytic
domain and the C-terminus (antigen 25C and 27C) mainly
comprised the hemagglutinin/adhesin region. We determined
the immunogenicity and induction of serum IgG levels as the
full length Kgp and RgpA. As expected, the C-terminus of
Kgp (25C) exhibited similar phenotypes as that of full length
Kgp. Our data of Kgp was in accordance with previous studies
that showed that the C-terminal hemagglutinin/adhesin region
primarily induced serum IgG antibodies in periodontitis patients
(36). Interestingly, the N-terminal catalytic domain of RgpA
(27N) exhibited a higher value of AUC (0.915) than the C-
terminus (AUC = 0.75) and other variants of Kgp (antigen
25N and 25C). Previous studies have demonstrated the reactivity
of the serum IgG antibodies from periodontitis patients to the
hemagglutinin/adhesin regions of Kgp and RgpA (44–46). Our
results for RgpA did not contradict those from previous reports.
These studies also showed the induction of serum IgG reactivity
with the catalytic domain, although the quantification of the
antibody level or serum IgG reactivity against each domain
of RgpA and Kgp has been limited (44–46). In this study,
the majority of the serum samples from periodontitis patients
strongly reacted to both antigens (27N and 27C) to the same
extent. Healthy subject sera exhibited a distinct reactivity with
27N and 27C. The reactivity of sera from healthy subjects against
27N was remarkably weaker compared to the reactivity against
27C, suggesting that antigen 27N imparts higher specificity. As
a result, 27N was associated with a higher AUC (0.915) showing
outstanding discrimination in screening periodontitis patients.
Taken together, we have demonstrated that serum IgG levels
in periodontitis patients were the highest against recombinant
Arg-gingipain (RgpA) among the antigens expressed in P.
gingivalis. Moreover, the N-terminus of recombinant RgpA
was the most appropriate antigen for screening periodontitis
patients. Using this antigen (N-terminus of RgpA) could
potentially lead to the development of an accurate and rapid
diagnostic kit for periodontitis. Given that antibody levels
did not correlate with the degree of bone loss in this study,
clinical examination for the severity of periodontal disease may
require the combination of several biomarkers. In contrast, at
least, it is possible to identify P. gingivalis infection for the
diagnosis of periodontitis-associated systemic diseases. Finally,
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FIGURE 6 | Serum IgG responses to the recombinant antigens as determined by dot blot analysis. (A) The panel shows a scheme of the proteins spotted.
Representative results of the sera used from healthy individuals (B: H1–H10) and patients with periodontitis (C: P1–P20) are shown. Approximately 50 ng of each
protein was spotted on the membrane, and sera were used at a dilution of 1:2,500. (D) Spot intensities were normalized relative to the background signals and
represented as relative intensities. Mean values and standard errors are shown on the right. **P < 0.01, *P < 0.05, N, N-terminal half; C, C-terminal half; H, Healthy
control; P, Patients with periodontitis.
further experiments need to be performed with a larger sample
study to determine if this antigen may be a biomarker for
periodontitis and to understand the link between periodontitis
and systemic diseases.
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FIGURE 7 | Receiver operative characteristic (ROC) curve analysis to evaluate
the diagnostic capacity of individual recombinant antigens (25N, 25C, 27N,
and 27C) to distinguish between periodontitis patients and healthy individuals.
(A) ROC curves were generated as described by Ekuseru-Toukei 2010 (Social
Survey Research Information Co., Ltd.) using the spot intensities from the dot
blot analysis (Figure 6). (B) The values of AUC with 95% confidence interval
(CI) and sensitivity/specificity with optimal cut-offs are presented in the lower
panel. N, N-terminal half; C, C-terminal half.
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